LONDON--(BUSINESS WIRE)--Lung cancer is one of the most common cancer types across the world. It is also the most common cause of cancer-related deaths globally. The mortality rate of lung cancer is increasing significantly, which creates a huge opportunity for vendors in the market. Thus, the rising prevalence of lung cancer owing to increasing geriatric population and lifestyle changes will fuel the growth of the lung cancer therapeutics market during the forecast period. Furthermore, this industry research report also presents a competitive analysis of the market by type (non-small-cell lung cancer and small-cell lung cancer) and geography (Asia, Europe, North America, and ROW).
Competitive vendor landscape
The global lung cancer therapeutics market is highly competitive with major vendors such as Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, and Pfizer Inc, competing on the basis of price, quality, and market presence.
“The indications of lung cancer cannot be completely treated with targeted therapies such as immunomodulators. Thus, there is a high need for therapies which can provide complete treatment of lung cancer and do not have any adverse effects. This has resulted in the development of various regenerative therapies such as gene therapy, which is helping to reduce the prevalence of lung cancer. The popularity of regenerative therapies will increase during the forecast period, which will have a significant impact on the growth of the lung cancer therapeutics market,” says a senior analyst at Technavio.
Top five lung cancer therapeutics market vendors
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company owns and operates a biopharmaceuticals business which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines that help patients prevail over serious diseases. The company offers drugs for the treatment of lung cancer which include OPDIVO, and VePesid.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd has business operations in two segments such as pharmaceuticals, and diagnostics. The company’s pharmaceuticals segment covers science, which can be used to create effective medicines to treat patients. The company’s offerings in the lung cancer therapeutics market include ALECENSA, TECENTRIQ, AVASTIN, and TARCEVA.
Merck & Co., Inc.
Merck & Co., Inc. owns and operates businesses in various segments including pharmaceuticals, and animal health. The company offers human health pharmaceuticals and vaccine products through its pharmaceutical segment. Merck & Co. offers KEYTRUDA, which is a PD-1 inhibitor approved for the treatment of NSCLC.
Novartis AG
Novartis AG is one of the leading manufacturers of innovative medicines with two business units, namely Pharmaceuticals and Novartis Oncology. The company offers HYCAMTIN, ZYKADIA, and TAFINLAR, which are used for the treatment of lung cancer.
Pfizer Inc.
Pfizer Inc. owns and operates businesses in two segments including innovative health, and essential health. Through its innovative health segment, the company offers internal medicine, vaccines, oncology products, inflammation and immunology products, rare disease products, and consumer healthcare products. The company’s product offerings include TOPOSAR, XALKORI, and VIZIMPRO.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Non-small Cell Lung Cancer Drugs Market 2019-2023 - The market research study identifies AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc as the leading players in the global non-small cell lung cancer drug market.
- Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2019-2023 - The market research study identifies Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., and Novartis AG as the leading players in the global epidermal growth factor receptor (EGFR) inhibitors market.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
